Navigation Links
A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Date:2/21/2013

uvir. The study concluded that the drug is effective in treating Hepatitis C patients who could not be cured by existing medications that contained pegylated interferon. Interferon is an ingredient loaded with side effects that often led to patients discontinuing therapy. With this, Gilead is on track to file regulatory applications for the drug in the United States and Europe in the second quarter. The results mark a remarkable run for the company after taking less than 16 months to finish its Phase III phase. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.NationalTradersAssociation.org/r/full_research_report/6e69_GILD]

--

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1(702)212-4493


'/>"/>
SOURCE National Traders Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
8. inVentiv Health Selected to Provide Sales Operations Support for Santarus
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
11. Nations Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... Aug. 7 Kensey Nash Corporation today announced an ... along with the trademark, inventory and other assets associated ... the terms of the agreement, the Company and Biomet ... agreement. Pursuant to the agreement, following a brief transition ...
... , , SAN MATEO, Calif., Aug. ... , , , Granted ... non-diabetic adults, either alone or in combination with other medicinal products for pain ... (Astellas) for commercialization of Qutenza in Europe, Middle East and Africa, including commercialization ...
... , , SAN MARINO, ... VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. ... University of Colorado Professor M. Karen Newell called "metabolic disruption ... to generate energy from glucose or from fatty acids. ...
Cached Biology Technology:Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... protein that helps pack DNA into the cell nucleus has ... researchers found that the protein, histone H1, also takes part ... all proteins are made. The study appeared online May ... A human cell,s genetic material is so vast that it ...
... of the extinction of woolly mammoths and other large mammals ... fallen victim to the same type of "trophic cascade" of ... the global decline of predators such as wolves, cougars, and ... originally begun by human disruption of ecosystems, a new study ...
Cached Biology News:CryoSat-2 exceeding expectations 2Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 2'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 4
... The Luminex 200 IS System is ideal ... Upstate's Beadlyte reagents. This system contains the ... developed by Luminex. The user can design ... kits. The system has fully integrated graphing ...
...
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... Includes: Sufficient library for 10 separate ... independent sequences, -28 gIII Sequencing Primer ... -96 gIII Sequencing Primer (100 pmol), ... coli strain ER2738, Control target (Streptavidin) ...
Biology Products: